AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
AN2 Therapeutics will present a poster detailing the design of its planned Phase 2 trial of oral epetraborole in phlebotomy-dependent polycythemia vera at the 18th International Congress on Myeloproliferative Neoplasms in Brooklyn on October 29-30, 2026. This is a trial-design disclosure rather than new clinical data; the poster will be shown during the Thursday evening session (poster 148).
Key figures
- Drug Name
- epetraborole
- Phase Of Trial
- Phase 2
- Congress
- 18th International Congress on Myeloproliferative Neoplasms, Oct 29-30, 2026, Brooklyn, NY
- Poster number
- 148
- Trial indication
- polycythemia vera (phlebotomy-dependent PV)
- Phase2 studies expected active 2026
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.